Browse IL6R

Summary
SymbolIL6R
Nameinterleukin 6 receptor
Aliases CD126; IL-6R-1; IL-6RA; IL6QA; IL6RQ; gp80; CD126 antigen; IL-6 receptor subunit alpha; IL-6R 1; membrane gl ......
Chromosomal Location1q21
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Isoform 1: Basolateral cell membrane; Single-pass type I membrane protein.; SUBCELLULAR LOCATION: Isoform 2: Secreted.
Domain PF00047 Immunoglobulin domain
PF09240 Interleukin-6 receptor alpha chain
Function

Part of the receptor for interleukin 6. Binds to IL6 with low affinity, but does not transduce a signal. Signal activation necessitate an association with IL6ST. Activation may lead to the regulation of the immune response, acute-phase reactions and hematopoiesis.; FUNCTION: Low concentration of a soluble form of IL6 receptor acts as an agonist of IL6 activity.

> Gene Ontology
 
Biological Process GO:0001503 ossification
GO:0001649 osteoblast differentiation
GO:0001819 positive regulation of cytokine production
GO:0002251 organ or tissue specific immune response
GO:0002384 hepatic immune response
GO:0002526 acute inflammatory response
GO:0002548 monocyte chemotaxis
GO:0002685 regulation of leukocyte migration
GO:0002687 positive regulation of leukocyte migration
GO:0002688 regulation of leukocyte chemotaxis
GO:0002690 positive regulation of leukocyte chemotaxis
GO:0006953 acute-phase response
GO:0007259 JAK-STAT cascade
GO:0007260 tyrosine phosphorylation of STAT protein
GO:0018108 peptidyl-tyrosine phosphorylation
GO:0018212 peptidyl-tyrosine modification
GO:0030278 regulation of ossification
GO:0030335 positive regulation of cell migration
GO:0030595 leukocyte chemotaxis
GO:0031016 pancreas development
GO:0031018 endocrine pancreas development
GO:0032103 positive regulation of response to external stimulus
GO:0032602 chemokine production
GO:0032635 interleukin-6 production
GO:0032642 regulation of chemokine production
GO:0032675 regulation of interleukin-6 production
GO:0032722 positive regulation of chemokine production
GO:0032755 positive regulation of interleukin-6 production
GO:0033002 muscle cell proliferation
GO:0035270 endocrine system development
GO:0040017 positive regulation of locomotion
GO:0042503 tyrosine phosphorylation of Stat3 protein
GO:0042509 regulation of tyrosine phosphorylation of STAT protein
GO:0042516 regulation of tyrosine phosphorylation of Stat3 protein
GO:0042517 positive regulation of tyrosine phosphorylation of Stat3 protein
GO:0042531 positive regulation of tyrosine phosphorylation of STAT protein
GO:0042742 defense response to bacterium
GO:0045667 regulation of osteoblast differentiation
GO:0045669 positive regulation of osteoblast differentiation
GO:0045778 positive regulation of ossification
GO:0046425 regulation of JAK-STAT cascade
GO:0046427 positive regulation of JAK-STAT cascade
GO:0048659 smooth muscle cell proliferation
GO:0048660 regulation of smooth muscle cell proliferation
GO:0048661 positive regulation of smooth muscle cell proliferation
GO:0050730 regulation of peptidyl-tyrosine phosphorylation
GO:0050731 positive regulation of peptidyl-tyrosine phosphorylation
GO:0050829 defense response to Gram-negative bacterium
GO:0050900 leukocyte migration
GO:0050920 regulation of chemotaxis
GO:0050921 positive regulation of chemotaxis
GO:0051272 positive regulation of cellular component movement
GO:0060326 cell chemotaxis
GO:0070102 interleukin-6-mediated signaling pathway
GO:0070120 ciliary neurotrophic factor-mediated signaling pathway
GO:0070741 response to interleukin-6
GO:0071354 cellular response to interleukin-6
GO:0071674 mononuclear cell migration
GO:0097191 extrinsic apoptotic signaling pathway
GO:0097529 myeloid leukocyte migration
GO:0097696 STAT cascade
GO:0098542 defense response to other organism
GO:1904892 regulation of STAT cascade
GO:1904894 positive regulation of STAT cascade
GO:2000147 positive regulation of cell motility
Molecular Function GO:0004896 cytokine receptor activity
GO:0004897 ciliary neurotrophic factor receptor activity
GO:0004915 interleukin-6 receptor activity
GO:0005126 cytokine receptor binding
GO:0005138 interleukin-6 receptor binding
GO:0019838 growth factor binding
GO:0019955 cytokine binding
GO:0019981 interleukin-6 binding
GO:0070119 ciliary neurotrophic factor binding
GO:0070851 growth factor receptor binding
Cellular Component GO:0005896 interleukin-6 receptor complex
GO:0016323 basolateral plasma membrane
GO:0016324 apical plasma membrane
GO:0043235 receptor complex
GO:0045177 apical part of cell
GO:0070110 ciliary neurotrophic factor receptor complex
GO:0098802 plasma membrane receptor complex
> KEGG and Reactome Pathway
 
KEGG hsa04060 Cytokine-cytokine receptor interaction
hsa04066 HIF-1 signaling pathway
hsa04151 PI3K-Akt signaling pathway
hsa04630 Jak-STAT signaling pathway
hsa04640 Hematopoietic cell lineage
Reactome R-HSA-1280215: Cytokine Signaling in Immune system
R-HSA-168256: Immune System
R-HSA-6785807: Interleukin-4 and 13 signaling
R-HSA-6783589: Interleukin-6 family signaling
R-HSA-1059683: Interleukin-6 signaling
R-HSA-5683057: MAPK family signaling cascades
R-HSA-112411: MAPK1 (ERK2) activation
R-HSA-5684996: MAPK1/MAPK3 signaling
R-HSA-110056: MAPK3 (ERK1) activation
R-HSA-112409: RAF-independent MAPK1/3 activation
R-HSA-162582: Signal Transduction
R-HSA-449147: Signaling by Interleukins
Summary
SymbolIL6R
Nameinterleukin 6 receptor
Aliases CD126; IL-6R-1; IL-6RA; IL6QA; IL6RQ; gp80; CD126 antigen; IL-6 receptor subunit alpha; IL-6R 1; membrane gl ......
Chromosomal Location1q21
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between IL6R and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 
  Literatures describing the relation between IL6R and anti-tumor immunity in human cancer.
PMID Cancer type Relation to immunity Evidence sentences
26216383Ovarian CarcinomaInhibit immunityInterleukin-6 is associated with chemoresistance and an immune-suppressive tumor microenvironment. Functional IL-6R blocking is feasible and safe in EOC patients treated with carboplatin/(pegylated liposomal)doxorubicin, using 8 mg/kg tocilizumab.
22653638MelanomaInhibit immunityHigh amounts of IL-6, a key cytokine of immunosuppres-sion and decreased quality of life in tumor-bearing hosts. To block IL-6-signaling in vivo, tumor-bearing mice wereadministered with anti-IL-6R mAb. Anti-IL-6 receptor mAb eliminates myeloid-derived suppressor cells and inhibits tumor growth by enhancing T-cell responses.
21926464MelanomaPromote immunity (infiltration)Inflammatory cytokines such as IL-6 exert tumor-promoting activities by driving growth and survival of neoplastic cells. Mechanistically, IL-6 produced by nonhematopoietic stromal cells acted cooperatively with soluble IL-6 receptor-α and thermally induced gp130 to promote E/P-selectin- and ICAM-1-dependent extravasation of cytotoxic T cells in tumors.
Summary
SymbolIL6R
Nameinterleukin 6 receptor
Aliases CD126; IL-6R-1; IL-6RA; IL6QA; IL6RQ; gp80; CD126 antigen; IL-6 receptor subunit alpha; IL-6R 1; membrane gl ......
Chromosomal Location1q21
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of IL6R in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolIL6R
Nameinterleukin 6 receptor
Aliases CD126; IL-6R-1; IL-6RA; IL6QA; IL6RQ; gp80; CD126 antigen; IL-6 receptor subunit alpha; IL-6R 1; membrane gl ......
Chromosomal Location1q21
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of IL6R in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)14120.3540.336
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)650.5170.756
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)870.2370.845
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 916-0.1730.662
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-0.6280.691
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470.3990.836
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.3330.388
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 1511-0.0120.994
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 11120.6440.739
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 480.3210.796
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 280.480.794
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.3830.00685
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of IL6R in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27733.703.70.27
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27593.703.70.314
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21170001
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13110001
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 91611.16.24.91
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 592011.18.91
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38270001
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22130001
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolIL6R
Nameinterleukin 6 receptor
Aliases CD126; IL-6R-1; IL-6RA; IL6QA; IL6RQ; gp80; CD126 antigen; IL-6 receptor subunit alpha; IL-6R 1; membrane gl ......
Chromosomal Location1q21
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of IL6R. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolIL6R
Nameinterleukin 6 receptor
Aliases CD126; IL-6R-1; IL-6RA; IL6QA; IL6RQ; gp80; CD126 antigen; IL-6 receptor subunit alpha; IL-6R 1; membrane gl ......
Chromosomal Location1q21
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of IL6R. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by IL6R.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolIL6R
Nameinterleukin 6 receptor
Aliases CD126; IL-6R-1; IL-6RA; IL6QA; IL6RQ; gp80; CD126 antigen; IL-6 receptor subunit alpha; IL-6R 1; membrane gl ......
Chromosomal Location1q21
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of IL6R. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolIL6R
Nameinterleukin 6 receptor
Aliases CD126; IL-6R-1; IL-6RA; IL6QA; IL6RQ; gp80; CD126 antigen; IL-6 receptor subunit alpha; IL-6R 1; membrane gl ......
Chromosomal Location1q21
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of IL6R expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolIL6R
Nameinterleukin 6 receptor
Aliases CD126; IL-6R-1; IL-6RA; IL6QA; IL6RQ; gp80; CD126 antigen; IL-6 receptor subunit alpha; IL-6R 1; membrane gl ......
Chromosomal Location1q21
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between IL6R and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolIL6R
Nameinterleukin 6 receptor
Aliases CD126; IL-6R-1; IL-6RA; IL6QA; IL6RQ; gp80; CD126 antigen; IL-6 receptor subunit alpha; IL-6R 1; membrane gl ......
Chromosomal Location1q21
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting IL6R collected from DrugBank database.
> Drugs from DrugBank database
 

  Details on drugs targeting IL6R.
ID Name Drug Type Targets #Targets
DB06273TocilizumabBiotechIL6R1
DB11767SarilumabBiotechFCGR1A, FCGR2A, FCGR2B, FCGR3A, FCGR3B, IL6R6